triflusal

Small moleculeexperimental

Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a derivative of acetylsalicylic acid in which a hydrogen atom on the benzene ring has been replaced by a trifluoromethyl group. Trade names include Disgren, Grendis, Aflen and Triflux. — Wikipedia

Clinical trial activity

6 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
3

Earliest trial started Jul 1, 2002 (NCT00162799)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O
Mol. weight
248.16 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-acetoxy-4-trifluoromethylbenzoic acid
  • 2- (acetyloxy)-4-(trifluoromethyl)benzoic acid
  • disgren
  • disgren
  • triflusal
  • triflusal
  • triflusal
  • triflusal
  • triflusal
  • triflusal
  • triflusal
  • triflusal

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02904109Phase 2Sep 13, 2016University of Basel
NCT02616497Phase 4Sep 1, 2015University of Ioannina
NCT02321852Phase 2Jan 1, 2015University of Basel
NCT01612273Phase 4Apr 1, 2011Yonsei University
NCT01174693Phase 4Mar 1, 2010Myung In Pharmaceutical Company, Yonsei University
NCT00162799Phase 2Jul 1, 2002J. Uriach and Company
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of BaselAcademic/Hospital2212015
Yonsei UniversityAcademic/Hospital2212010
J. Uriach and CompanyFor profit1112002
Myung In Pharmaceutical CompanyFor profit1012010
University of IoanninaAcademic/Hospital1112015
5 organizations
Page 1 / 1